Kinneret Savitsky - Compugen Director

CGEN Stock  ILA 755.00  20.00  2.72%   

Director

Dr. Kinneret Livnat Savitsky was appointed Director at Compugen Ltd. effective June 11, 2018. Dr. Livnat Savitsky work experience includes the following roles Vice President Biology, Research Development at the Company, Interim Chief Executive Officer and Board Member of FutuRx Ltd., Director at various companies, Consultant and Chief Executive Officer at BioLineRx Ltd. since 2018.
Age 50
Tenure 6 years
Phone(972) 3 765 8555
Webwww.cgen.com
Livnat Savitsky holds a BS degree in Biochemistry from Tel Aviv University, a BS degree in Biology from The Hebrew University of Jerusalem and a MS degree and a Doctorate of Science degree, both in Human Genetics from Tel Aviv University.

Compugen Management Efficiency

The company has return on total asset (ROA) of (0.2301) % which means that it has lost $0.2301 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4394) %, meaning that it generated substantial loss on money invested by shareholders. Compugen's management efficiency ratios could be used to measure how well Compugen manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 2.85 M in total debt with debt to equity ratio (D/E) of 0.03, which may suggest the company is not taking enough advantage from borrowing. Compugen has a current ratio of 9.41, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Compugen until it has trouble settling it off, either with new capital or with free cash flow. So, Compugen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Compugen sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Compugen to invest in growth at high rates of return. When we think about Compugen's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Dov NinvehElbit Systems
71
Kalman KaufmanTower Semiconductor
72
Joseph CowanNice
70
Yuli TamirElbit Systems
65
Michael BerelowitzKamada
74
Shmuel RubinsteinKamada
78
Adrian PercyEvogene
N/A
Sagi KablaTower Semiconductor
38
Noit LeviTower Semiconductor
N/A
Joe CowanNice
66
Gwen MelincoffKamada
67
Avraham AsheriElbit Systems
77
Leon RecanatiEvogene
71
Michael AnghelEvogene
78
Adina MakoverEvogene
66
Ziv KopEvogene
46
Leo ApothekerNice
65
Yehoshua GleitmanElbit Systems
69
Ehood NisanElbit Systems
51
Dan FalkNice
74
Tuvia ShohamKamada
70
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel. COMPUGEN operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 68 people. Compugen (CGEN) is traded on Tel Aviv Stock Exchange in Israel and employs 73 people.

Management Performance

Compugen Leadership Team

Elected by the shareholders, the Compugen's board of directors comprises two types of representatives: Compugen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Compugen. The board's role is to monitor Compugen's management team and ensure that shareholders' interests are well served. Compugen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Compugen's outside directors are responsible for providing unbiased perspectives on the board's policies.
Joshua Shemer, Independent External Director
Rivka Schwartz, VP Discovery
Paul Sekhri, Chairman of the Board
Martin Gerstel, Chairman of the Board
Zurit Levine, Vice President - Research and Discovery
Ari Krashin, Chief Financial Officer
Anat CohenDayag, President, Chief Executive Officer, Director
Ruth Arnon, Independent Director
Yair Aharonowitz, Independent External Director
Eran Dor, Gen Sec
Oliver Froescheis, Sr Devel
Alberto Sessa, Chief Officer
Michal Preminger, Director
Henry MD, VP Officer
Dov Hershberg, Director
Arie Ovadia, Independent External Director
Eran Perry, Director
Sanford Zweifach, Director
Gilead Halevy, Director
Yvonne Naughton, Head Communications
Kinneret Savitsky, Director
Henry Adewoye, Chief Medical Officer
Dorit Amitay, VP HR
JeanPierre Bizzari, Director
John Hunter, VP of Antibody RandD and Site Head of Compugen USA Inc

Compugen Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Compugen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Compugen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Compugen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Compugen will appreciate offsetting losses from the drop in the long position's value.

Moving against Compugen Stock

  0.69ITYF Itay Financial AAPairCorr
  0.41BLRX BioLine RXPairCorr
The ability to find closely correlated positions to Compugen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Compugen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Compugen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Compugen to buy it.
The correlation of Compugen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Compugen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Compugen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Compugen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Compugen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Compugen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Compugen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Compugen Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Compugen. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Compugen Stock refer to our How to Trade Compugen Stock guide.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Complementary Tools for Compugen Stock analysis

When running Compugen's price analysis, check to measure Compugen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compugen is operating at the current time. Most of Compugen's value examination focuses on studying past and present price action to predict the probability of Compugen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compugen's price. Additionally, you may evaluate how the addition of Compugen to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Please note, there is a significant difference between Compugen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Compugen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Compugen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.